Editorial: Real World Outcomes of Lymphoma From India

Lalit Kumar; Naresh Kn; Sumeet Gujral; Padmaj Kulkarni; Martin R Stockler; Reena Nair

doi:10.3389/fonc.2022.922370

Editorial: Real World Outcomes of Lymphoma From India

Front Oncol. 2022 Jul 19:12:922370. doi: 10.3389/fonc.2022.922370. eCollection 2022.

Authors

Lalit Kumar¹, Naresh Kn², Sumeet Gujral³, Padmaj Kulkarni⁴, Martin R Stockler⁵, Reena Nair⁶

Affiliations

¹ Department of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
² Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
³ Department of Pathology, Tata Memorial Hospital, Mumbai, India.
⁴ Department of Medical Oncology, Deenanath Mangeshkar Hospital & Research Center, Pune, India.
⁵ Department of Medical Oncology, National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁶ Department of Clinical Hematology, Tata Medical Center, Kolkata, India.

No abstract available

Keywords: Hodgkin lymphoma; biosimilars; diffuse large B cell lymphoma; real world evidence; real world outcomes; targeted therapies; targeted therapy.

Publication types

Editorial